Ligand Pharmaceuticals/ US53220K5048 /
| 2024-11-08 9:59:40 PM | Chg. -8.65 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 121.12USD | -6.66% | 11,237 Turnover: 1.35 mill. |
-Bid Size: - | -Ask Size: - | 2.22 bill.USD | - | 40.15 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 7.1850 | 14.4340 | 20.5110 | 12.4820 | 15.6070 | ||||||
| Intangible Assets | 210.4480 | 595.3300 | 551.0400 | 342.4550 | 299.6060 | ||||||
| Long-Term Investments | - | - | - | - | 12.5950 | ||||||
| Fixed Assets | 371.2700 | 861.7260 | 832.8390 | 499.0670 | 549.7870 | ||||||
| Inventories | 7.2960 | 26.4870 | 27.3260 | 13.2940 | 23.9690 | ||||||
| Accounts Receivable | 30.3870 | 56.8470 | 85.4530 | 30.4240 | 32.9170 | ||||||
| Cash and Cash Equivalents | 71.5430 | 47.6190 | 19.5220 | 45.0060 | 22.9540 | ||||||
| Current Assets | 1,123.6450 | 500.5590 | 464.7510 | 263.6010 | 237.4290 | ||||||
| Total Assets | 1,494.9150 | 1,362.2850 | 1,297.5900 | 762.6680 | 787.2160 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 2.4200 | 3.7840 | 8.4030 | 5.3070 | 2.4270 | ||||||
| Long-term debt | 638.9590 | 442.2930 | 320.7170 | 0.0000 | 0.0000 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 727.6830 | 652.7600 | 476.4310 | 165.1830 | 86.3030 | ||||||
| Share Capital | .0170 | .0160 | .0170 | .0170 | .0180 | ||||||
| Total Equity | 767.2320 | 709.5250 | 821.1590 | 597.4850 | 700.9130 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 1,494.9150 | 1,362.2850 | 1,297.5900 | 762.6680 | 787.2160 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 120.2820 | 186.4190 | 277.1330 | 196.2450 | 131.3140 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 807.0760 | 25.8450 | 78.8950 | 3.0370 | 11.9420 | ||||||
| Interest Income | -7.3150 | -19.3420 | -18.7400 | .2470 | 7.0550 | ||||||
| Income Before Taxes | 796.6390 | -10.5380 | 47.2980 | 36.0110 | 63.6600 | ||||||
| Income Taxes | -167.3370 | 7.5530 | 9.8400 | -41.2300 | -9.8410 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 629.3020 | -2.9850 | 57.1380 | -33.3610 | 52.1540 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -29.3360 | 54.5860 | 78.7980 | 137.8500 | 49.5770 | ||||||
| Cash Flow from Investing Activities | 466.9180 | 231.6480 | 30.5230 | 163.6240 | -11.6820 | ||||||
| Cash Flow from Financing | -485.1720 | -310.5450 | -137.7610 | -275.9900 | -59.9470 | ||||||
| Decrease / Increase in Cash | -47.5900 | -24.3110 | -28.4400 | 25.4840 | -22.0520 | ||||||
| Employees | - | - | - | - | - | ||||||
